Can the patient take hydrochlorothiazide if she has gout?
No, hydrochlorothiazide should be switched to an alternative antihypertensive agent when feasible in patients with gout. 1
Guideline Recommendation
The 2020 American College of Rheumatology Guideline for the Management of Gout explicitly addresses this scenario and conditionally recommends switching hydrochlorothiazide to an alternate antihypertensive when feasible for patients with gout, regardless of disease activity 1. This recommendation is based on the known effects of HCTZ on serum uric acid concentrations, though the guideline emphasizes that switching should only occur when the potential benefits exceed the risks of medication change.
Evidence Supporting the Recommendation
Risk of Gout with HCTZ
- Large population-based data demonstrates that current use of thiazide diuretics carries a 1.70-fold increased risk of incident gout (95% CI 1.62-1.79) compared to past use 2
- Loop diuretics show even higher risk (OR 2.64), while thiazide-like diuretics show intermediate risk (OR 2.30) 2
- Doses ≥25 mg/day of HCTZ significantly increase the risk for initiating anti-gout therapy (RR 1.99,95% CI 1.21-3.26), while lower doses show no significant increase 3
- The FDA label confirms that hyperuricemia or acute gout may be precipitated in certain patients receiving thiazide diuretics 4
Preferred Alternative: Losartan
The same ACR guideline conditionally recommends choosing losartan preferentially as an antihypertensive agent when feasible for patients with gout 1. Losartan is the only angiotensin II receptor blocker with demonstrated uricosuric effects that significantly lower uric acid levels 5. Research shows that current use of losartan can slightly attenuate the risk of gout in patients taking diuretics 2.
Clinical Decision Algorithm
If the patient requires diuretic therapy:
- Consider potassium-sparing diuretics, which showed no increased gout risk (OR 1.06,95% CI 0.91-1.23) 2
- If thiazide therapy is absolutely necessary, use the lowest effective dose (<25 mg/day) 3
If blood pressure control allows medication switching:
- Switch to losartan as the preferred alternative 1
- Consider calcium channel blockers, which also slightly attenuate gout risk 2
If the patient must remain on HCTZ:
- Ensure appropriate urate-lowering therapy is optimized
- Monitor for gout flares more closely
- Consider prophylactic therapy if initiating or adjusting urate-lowering treatment
Important Caveats
- Do not abruptly discontinue HCTZ without ensuring adequate blood pressure control with alternative agents
- The guideline emphasizes that medication changes should only occur when feasible and when benefits exceed risks 1
- Combined use of loop diuretics and thiazide diuretics carries the highest risk (OR 4.65) and should be particularly avoided 2
- While chlorthalidone is more potent for blood pressure control, it carries similar gout risk to HCTZ 6